GlassScriptPhysician profile
Brian G Everhart
NPI 1346262656
$7,226.56
in general payments reported to CMS, 2019-2025
52 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,171 · 2020: $371 · 2021: $1,189 · 2022: $922 · 2023: $1,319 · 2024: $1,080 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,488 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,488.40 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,424.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,028.11 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $564.61 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $540.04 | 2019-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $456.95 | 2019-2025 | |
| Amgen INC. | $401.67 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $391.71 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $314.36 | 2019-2025 | Eliquis, Camzyos |
| Astellas Pharma US INC | $251.78 | 2020-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $204.00 | 2019-2024 | Spravato |
| Astrazeneca Pharmaceuticals LP | $174.55 | 2019-2025 | Breztri, Farxiga |
| Amarin Pharma, INC. | $149.78 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $141.74 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $130.55 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $117.24 | 2019-2023 |
Show all 48 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Everhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.